ZURA BIO LIMITED Fair Value Adjustment of Warrants
ZURA BIO LIMITED (ZURA) reported Fair Value Adjustment of Warrants of $5.24 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-03-19
- ZURA BIO LIMITED fair value adjustment of warrants for the quarter ending 2024-12-31 was $0.00.
- ZURA BIO LIMITED fair value adjustment of warrants for the quarter ending 2024-09-30 was $3.87M.
- ZURA BIO LIMITED fair value adjustment of warrants for the quarter ending 2024-06-30 was $768.00K, a 44.36% increase year-over-year.
- ZURA BIO LIMITED fair value adjustment of warrants for the quarter ending 2024-03-31 was $606.00K.
- ZURA BIO LIMITED fair value adjustment of warrants for fiscal 2024 was $5.24M.
- ZURA BIO LIMITED fair value adjustment of warrants for fiscal 2023 was -$724.00K.
- ZURA BIO LIMITED fair value adjustment of warrants for fiscal 2022 was -$4.15M.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 4 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 7 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 10 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.87M derived: sum of 2 quarters · filed 2026-03-19 | $4.63M derived: sum of 3 quarters · filed 2026-03-19 | $5.24M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $3.87M 10-Q · filed 2025-11-13 | $4.63M derived: sum of 2 quarters · filed 2025-11-13 | $5.24M 10-Q · filed 2025-11-13 | $4.28M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $768.00K 10-Q · filed 2025-08-14 | $1.37M 10-Q · filed 2025-08-14 | $414.00K derived: sum of 3 quarters · filed 2025-08-14 | $295.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $606.00K 10-Q · filed 2025-05-08 | -$354.00K derived: sum of 2 quarters · filed 2025-05-08 | -$473.00K derived: sum of 3 quarters · filed 2025-05-08 | $59.00K derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$1.08M derived: sum of 2 quarters · filed 2025-03-25 | -$547.00K derived: sum of 3 quarters · filed 2025-03-25 | -$724.00K 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | -$119.00K 10-Q · filed 2024-11-07 | $413.00K derived: sum of 2 quarters · filed 2024-11-07 | $236.00K 10-Q · filed 2024-11-07 | $107.90K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $532.00K 10-Q · filed 2024-08-13 | $355.00K 10-Q · filed 2024-08-13 | $226.90K derived: sum of 3 quarters · filed 2024-08-13 | -$88.40K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$177.00K 10-Q · filed 2024-05-09 | -$305.10K derived: sum of 2 quarters · filed 2024-05-09 | -$620.40K derived: sum of 3 quarters · filed 2024-05-09 | -$3.78M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$128.10K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$443.40K derived: sum of 2 quarters · filed 2023-03-28 | -$3.60M derived: sum of 3 quarters · filed 2023-03-28 | -$4.15M 10-K · filed 2023-03-28 | ||||
| 2022-09-30 | -$315.30K 10-Q · filed 2022-11-14 | -$3.48M derived: sum of 2 quarters · filed 2022-11-14 | -$4.02M 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | -$3.16M 10-Q · filed 2022-08-12 | -$3.71M 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | -$543.87K 10-Q · filed 2022-05-13 | |||||||
| 2021-12-31 | -$10.24M 10-K · filed 2023-03-28 | |||||||
| 2021-09-30 | -$8.62M 10-Q · filed 2022-11-14 | -$8.62M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |